The pharmaceutical landscape is witnessing a shift toward therapies that prioritize both clinical efficacy and patient experience. A compelling example is the launch of TRYVIO in the U.S. and JERAYGO in the European Union—two brand names representing a novel desmopressin-based therapy created by Ferring Pharmaceuticals. This treatment targets nocturia caused by nocturnal polyuria, a...